Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study will test the efficacy and safety of different routes of administration of a DNA
vaccine in patients with HPV16+ CIN2/3. Subjects will be enrolled in one of six treatment
groups. Subjects enrolled in the first two groups will receive vaccination intradermally with
a needle-free delivery device. Subjects enrolled in groups 3 and 4 will receive vaccination
intramuscularly. Subjects enrolled in groups 5 and 6 will receive vaccine intralesionally.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)